Introduction
============

Nosocomial infections caused by multidrug resistant *Acinetobacter baumannii* are becoming increasingly common worldwide, especially in the intensive care setting ([@B63]). The success of this bacterium is facilitated by its ability to survive in a variety of environments compounded by its rapid ability to acquire multidrug resistance. Surface carbohydrates play key roles in the overall fitness and virulence of *A. baumannii* ([@B32]; [@B11]; [@B57]). *A. baumannii* produces high molecular weight capsular polysaccharide (CPS) which surrounds the outer membrane (Figure [1](#F1){ref-type="fig"}) ([@B44]). Comprised of tightly packed repeating oligosaccharide subunits (K units), CPS forms a discrete layer on the bacterial surface providing protection from diverse environmental conditions, assisting in evasion of host immune defenses, and increasing resistance to a number of antimicrobial compounds ([@B44]; [@B19]; [@B11]).

![Schematic representation of capsule polysaccharide assembly and export in *A. baumannii*. Synthesis begins with the initial transferase (Itr; maroon) located in the inner membrane (IM) transferring the first sugar of the repeating unit to a lipid carrier (Und-P; green circle). Subsequent sugars are then added to the growing unit by specific glycosyltransferases (Gtr; yellow) on the cytosolic side of the inner membrane. The capsule subunit (K unit) is then transferred to the periplasm via the integral membrane protein Wzx (dark blue). The sugar subunits are polymerized by the Wzy protein (purple) and the Wza/Wzb/Wzc complex (cyan, lime, red) coordinates high level polymerization and export of the growing chain, moving them to the outer membrane (OM). For glycosylation, PglL (orange) links the K units onto selected outer membrane proteins (OMP; dark green).](fmicb-09-03301-g001){#F1}

In *A. baumannii*, capsule assembly and export occurs via a Wzy-dependent pathway ([@B17]; [@B23]; [@B65]; [@B66]) (Figure [1](#F1){ref-type="fig"}). Typically consisting of 4--6 sugars, the K unit is assembled on the lipid carrier molecule undecaprenyl pyrophosphate (Und-P) which provides a scaffold for the growing sugar chain ([@B60]). The first sugar in the K unit is recruited by an inner membrane (IM)-bound initial transferase (Itr), followed by the sequential addition of sugars to the growing K unit by specific glycosyl transferase (Gtr) enzymes (Figure [1](#F1){ref-type="fig"}) ([@B66]). Each K unit is then transferred to the periplasmic side of the IM by the Wzx translocase and polymerized by Wzy, which transfers the growing polysaccharide chain from one Und-P carrier to the next incoming subunit (Figure [1](#F1){ref-type="fig"}) ([@B8]). After the CPS polymer is synthesized, it is transported to the cell surface via a highly co-ordinated process involving the interaction of three proteins; Wza, Wzb, and Wzc, that comprise the export machinery (Figure [1](#F1){ref-type="fig"}). CPS synthesis represents one arm of a bifurcated pathway, as these K units are also used to decorate certain surface proteins via *O*-linked protein glycosylation ([@B32]). In this case, single K units are transferred to recipient proteins by the *O*-oligosaccharyltransferase PglL (Figure [1](#F1){ref-type="fig"}) ([@B19]). In *A. baumannii*, protein glycosylation contributes to biofilm formation by enhancing initial attachment and maturation of biofilms, and pathogenicity as demonstrated in a number of animal infection models ([@B19]; [@B46]; [@B14]). Biofilm is a growth state in which bacterial communities are enclosed within an exopolysaccharide matrix and has been shown to play a significant role in *A. baumannii* persistence and resistance.

Other surface carbohydrates known to influence pathogenicity of *A. baumannii* include lipooligosaccharide (LOS) and the exopolysaccharide poly-β-(1-6)-*N*-acetylglucosamine (PNAG) ([@B40]; [@B57]). PNAG forms the cohesive "glue" of biofilms and constitutes a substantial proportion of biofilms ([@B7]; [@B33]). Unlike most Gram-negative bacteria, *A. baumannii* does not produce traditional lipopolysaccharide, but instead a similar surface glyco-conjugate, LOS, comprised of a lipid A core that lacks O-antigen ([@B23]; [@B26]). Loss of LOS production in *A. baumannii* decreases stability of the outer membrane leading to reduced fitness ([@B37]; [@B2]).

Although many carbohydrate moieties influence pathogenicity, it can be argued that CPS is a predominant virulence factor of *A. baumannii*. This review aims to consolidate what is known about *A. baumannii* capsule including selected structures, biosynthesis and gene organization, the role of CPS in virulence, and the potential for CPS as a target for future vaccine and drug development.

Genetic Organization of K Loci
==============================

As the complete genomes of more *A. baumannii* isolates become available, the true diversity of capsule structures present within this bacterium is becoming apparent. To date, over 100 unique capsule loci (KL) have been identified in *A. baumannii* (Figure [2A](#F2){ref-type="fig"}) ([@B48]). These regions typically range from 20 to 35 kb in size. Analysis of the genes directing CPS synthesis in ten complete *A. baumannii* genomes originally resulted in the designation of nine capsule types, KL1--KL9, which became the basis for a universal typing scheme for these loci ([@B23]). This scheme has subsequently expanded to accommodate the identification of new K loci. The chromosomal location of the K locus, between the *fkpA* and *lldP* genes, is highly conserved between *A. baumannii* strains and contains those genes required for the biosynthesis and export specific to each CPS type (Figure [2](#F2){ref-type="fig"}) ([@B17]; [@B23]). An exception to this rule are *A. baumannii* strains possessing KL19 and KL39 regions, where the gene encoding the Wzy polymerase, *wzy*, is found on a small genetic island elsewhere on the chromosome ([@B28]). Additionally, the genes required for some of the common sugars seen in CPS are found elsewhere. All K loci show a similar genetic configuration, a highly variable cluster of synthesis and transferase genes required for the biosynthesis of unique KL-type complex sugars, flanked on one side by the highly conserved CPS export genes, and on the other side by a set of genes encoding conserved simple sugars and precursors (Figure [2A](#F2){ref-type="fig"}). The *wzx* and *wzy* genes required for repeat-unit processing are highly variable between K loci (Figure [2A](#F2){ref-type="fig"}, light blue), indicating specificity for particular K unit structures and, in general, the order of *gtr* determinants, encoding specific glycosyltransferases within the KL regions, inversely corresponds with the order of action.

![Comparison of representative *A. baumannii* CPS biosynthesis gene clusters and corresponding structures. **(A)** Nucleotide sequences representing different KL regions focusing on genes between *fkpA* and *lldP* were obtained from the NCBI database and aligned using the Easyfig 2.2.2 tool ([@B49]). Genes are depicted by arrows and indicate direction of transcription whilst IS elements are represented by square boxes. Color scheme is based on homology to the putative function of gene products and are outlined in the key. Nucleotide sequence homology shared between regions is represented by color gradient. Figure is drawn to scale. Gene modules for sugar synthesis of interest are indicated, where Aci5Ac7Ac represents genes involved in the production of 5,7-di-*N*-acetylacineta- minic acid; [L]{.smallcaps}-Fuc*p*NAc, *N*-acetyl-[L]{.smallcaps}-fucosaminic acid; [D]{.smallcaps}-Fuc*p*NAc, *N*-acetyl-[D]{.smallcaps}-fucosaminic acid; 8eLeg*p*5Ac7Ac, 5,7-diacetamido-3,5,7,9- tetradeoxy-[L]{.smallcaps}-*glycero*- [D]{.smallcaps}-*galacto*-non-2-ulopyranosonic (di-*N*-acetyl-8-epilegionaminic) acid; [D]{.smallcaps}-Gal*p*NAcA, *N*-acetyl-[D]{.smallcaps}-galactosaminuronic acid; [D]{.smallcaps}-Qui*p*NAc4NAc, 2,4-diacetamido- 2,4,6-trideoxy-[D]{.smallcaps}-glucopyranose (*N*,*N*'-diacetyl-bacillosamine); [D]{.smallcaps}-Qui*p*NAc, *N*-acetyl-[D]{.smallcaps}-quinovosaminic acid; GlcNAc3NAcA4OAc, 2,3-diacetamido-2,3-dideoxy -α-[D]{.smallcaps}-glucuronic acid with an additional *O*-acetyl group; Pse*p*5Ac7Ac, 5,7-diacetamido-3,5,7,9-tetradeoxy-[L]{.smallcaps}-*glycero*-[L]{.smallcaps}-*manno*-non-2-ulosonic (pseudaminic) acid and Pse*p*5Ac7*R*Hb, 5-acetamido-3,5,7,9-tetradeoxy-7-(3-hydroxybutanoylamino)-[L]{.smallcaps}-*glycero*-[L]{.smallcaps}-*manno*-non-2-ulosonic acid. Genes of interest are labeled above corresponding gene, see text for further details. Genbank accession numbers for sequences used in gene alignment are as follows; KL12, JN107991.2 (38.5 kb region; base position range 2332--40832); KL13, MF522810.1 (38.2 kb region); KL49, KT359616.1 (34.5 kb region); KL53, MH190222.1 (23.4 kb region); KL19, KU165787.1 (23.8 kb); KL1, CP001172.1 (24.9 kb; base position range 366401 to 3691388); KL4, JN409449.3 (30.9 kb; base position range 2375 to 33327); KL3, CP012004.1, (25.4 kb; base position range 3762660--3788118); KL2, CP000863.1 (27.1 kb; base position range 77125--104246); KL6, KF130871.1 (25.5 kb); KL93, CP021345.1 30.3 kb (base position range 3338210--3368604) and KL37 KX712115.1 (23.4 kb). **(B)** Capsule structures corresponding to KL gene regions in **(A)** are shown. Percentage of *O*-acetylation of specific glycans from K53, K19, K1 are not represented in structural configurations ([@B28]; [@B47]).](fmicb-09-03301-g002){#F2}

The variable region of some KL gene clusters, such as KL37 and KL14, lack genes for complex sugar synthesis, as they only contain simple sugars in their K units ([@B1]; [@B24]). Also adding to their diversity, several KL regions contain redundant genes which are not required for the synthesis of the final K unit. For example KL8 and KL9 contain two *itr* genes ([@B23]) and KL37 has the *pgt1* phosphoglyceroltransferase, but no corresponding phosphoglycerol residue in the determined structure ([@B1]). Furthermore, in KL93, two insertion sequence elements (IS*Aba26* and IS*Aba22*) interrupt the *pgt1* determinant (Figure [2](#F2){ref-type="fig"}) ([@B21]). The genes required for specific sugar biosynthesis will not be discussed as these pathways have been covered previously and are beyond the scope of this review ([@B17]; [@B23]). Additionally, other genes located within the KL encode products predicted to be involved in acetylation or acylation modification of specific glycans (Figure [2A](#F2){ref-type="fig"}, pink). Although examination of the K loci can reveal a lot about K unit structures, chemical analysis and biochemical testing is required to determine exact structures and identify specific linkages between repeat sugars.

CPS Structures
==============

The earliest studies on CPS serotyping of *A. baumannii* were driven by the need to develop a method to discriminate *A. baumannii* isolates from other *Acinetobacter* species, as phenotypic analysis was burdened with ambiguity and misidentification ([@B53]). As described above, there is phenomenal diversity seen in *A. baumannii* CPS biosynthesis gene clusters, which translates into the diversity seen in K unit structure ([@B17]; [@B23]). Collectively, over 40 diverse *A. baumannii* K unit structures have been elucidated thus far using NMR spectroscopy and chemical analysis. K unit structures differ in sugar composition. They may include derivatives of common UDP-linked sugars such as glucose, galactose and glucuronic acid or rare and atypical sugars such as non-2-ulosonic acids. Structures vary in length and may consist of only two residues, as seen for K53 type CPS ([@B47]), or up to five or six monosaccharides, such as that seen in K37 (Figure [2B](#F2){ref-type="fig"}) ([@B1]). Structures also differ in the linkages both within and between K units resulting in the production of K units that are linear or involve side branches, as seen in K1 and K93, respectively (Figure [2B](#F2){ref-type="fig"}) ([@B28]; [@B21]). Differences in the location of specific glycosidic bonds and *O*-acetylation patterns of various oligosaccharides within a structure also contribute to K unit diversity.

Variation between K unit structures may be subtle, for example, K12 and K13 differ only by the linkage of two glycans, which requires the use of an alternate Wzy polymerase; accordingly, the K loci of both strains are identical except for the *wzy* gene (Figure [2](#F2){ref-type="fig"}). Alternatively the variation may be striking, such as the incorporation of rare sugars including pseudaminic, legionaminic, or acinetaminic acid derivatives as seen in K2/6, K49, and K12/13 structures, respectively (Figure [2](#F2){ref-type="fig"}) ([@B25], [@B24]; [@B55]; [@B22]). Interestingly, acinetaminic acid derivatives have only been identified in *A. baumannii* and are found nowhere else in nature ([@B27]). Additionally, some K units incorporate unique derivatives of specific glycans, for instance the pseudaminic acid of K93 is acetylated with a (*R*)-3-hydroxybutanoyl group ([@B21]), whereas in K2 and K6 the pseudaminic acid is non-acetylated (Figure [2](#F2){ref-type="fig"}). Furthermore, the structure of K4 is unique as it contains only aminosugars, D-Qui*p*NAc, and one terminal *N*-acetyl-[D]{.smallcaps}-galactosamine (D-Gal*p*NAcA) branch which is capped with a pyruvyl group, a rare motif and the first to be described in *Acinetobacter* (Figure [2A](#F2){ref-type="fig"}, black) ([@B29]). As the number of K unit structures elucidated increases, so does the confidence to infer the K unit structure from analysis of the biosynthesis clusters positioned in the *A. baumannii* KL. However, although informative, an understanding of the role CPS plays in pathogenesis is important to apply this knowledge to improving outcomes of *A. baumannii* infections.

Role in Virulence, Antimicrobial Resistance, and Persistence
============================================================

It is beyond doubt that the presence of CPS is essential for *A. baumannii* pathogenicity. Not only is it necessary for evasion of host immune defenses ([@B44]; [@B11]), but it is important for resistance to antimicrobial compounds and survival in adverse environments ([@B34]; [@B44]; [@B11]). CPS mediates immune evasion in many *A. baumannii* strains by limiting interactions between immunogenic surface structures of the bacteria and host defenses ([@B40]; [@B67]; [@B44]; [@B54]; [@B32]; [@B11]; [@B56]). The abolition of capsule in multiple different *A. baumannii* strains has shown reduced survival in human serum and ascites fluid, and attenuation in rat and murine infection models ([@B44]; [@B54]; [@B32]; [@B45]). Furthermore, the up-regulation of capsule production in the commonly utilized *A. baumannii* strain ATCC 17978 (K3 CPS type) increased serum resistance and virulence in a mouse infection model ([@B11]). Moreover, novel antimicrobial treatments could be developed for specific CPS types, for example those containing pseudaminic acid, as its presence has been correlated with enhanced virulence ([@B16]; [@B20]).

Besides protection from host defenses, in *A. baumannii* CPS production increases resistance to a range of antimicrobial compounds, including those used for disinfection in clinical settings ([@B11]; [@B51]; [@B4]). Furthermore, growth of *A. baumannii* in sub-inhibitory levels of antimicrobials influences CPS production. For example, exposure to the antibiotics chloramphenicol or erythromycin led to enhanced capsule synthesis in ATCC 17978 ([@B11]) and meropenem exposure selected for mutations leading to a loss in CPS production in the isolate 37662 ([@B4]). Studies conducted on a broader range of *A. baumannii* strains are required to identify if the protection against antimicrobials afforded by CPS is strain specific, capsule-type specific, or universal.

The ability of *A. baumannii* to persist in the clinical environment has undoubtedly enhanced colonization and infections in susceptible patients. *A. baumannii* is capable of surviving for months on hospital surfaces such as bed rails, furniture and medical devices, providing a reservoir that is often the source of transmission and infection ([@B59]; [@B10]). The remarkable desiccation tolerance of *A. baumannii* is thought to be due to a "bust or boom" strategy, where a persistent subpopulation of cells survive at the expense of dying cells; CPS enhances desiccation tolerance by providing a physical barrier facilitating water retention ([@B42]; [@B58]; [@B10]; [@B3]). A direct role for CPS in desiccation resistance was recently demonstrated in the *A. baumannii* strain AB5075 (K25 CPS type). In this study, the acapsular variant of AB5075 displayed a 2.5-fold reduction in viability compared to the parental strain ([@B50]). Furthermore, in two close relatives of *A. baumannii*, *Acinetobacter calcoaceticus* and *Acinetobacter baylyi*, production of exopolysaccharide and/or CPS has been shown to promote desiccation survival ([@B41]; [@B39]). In addition to influencing resistance to desiccation, CPS has been associated with other virulence traits including motility ([@B35]; [@B18]) and the production of biofilm ([@B54]; [@B32]), thus cementing its role as a pathogenic factor.

Recent studies have linked the phase-variable phenotype of *A. baumannii* AB5075 with alterations in CPS production, as highly virulent opaque variants produce a CPS layer with twice the thickness of their translucent counterparts ([@B6]). This transition from translucent to opaque also dramatically increased the pathogenic potential of *A. baumannii* AB5075. Resistance to common hospital disinfectants and a subset of aminoglycoside antibiotics were also increased ([@B51]; [@B6]) and opaque variants were also more resistant to human lysozyme, the cathelicidin-related antimicrobial peptide LL37 and hydrogen peroxide compared to translucent colonies ([@B6]). Furthermore, opaque isolates had an increased tolerance to desiccated conditions and out-competed translucent counterparts in a mouse infection model ([@B6]). As multiple factors are involved in phase variation, further studies were performed to determine the contribution of CPS production to the more virulent opaque phenotype. In a following publication, the authors demonstrated that an acapsular variant was significantly more susceptible to lysozyme and disinfectants compared to its opaque AB5075 wild-type parent ([@B50]). Interestingly, there was no difference in resistance to LL-37 and hydrogen peroxide between the opaque wild-type and acapsular strains, suggesting factors other than CPS production lead to this phenotype for opaque variants of *A. baumannii* ([@B50]).

Regulation of CPS Production
============================

Environmental cues, such as temperature, osmotic pressure and changes in metabolite and ion availability can influence bacterial CPS production ([@B13]; [@B30]; [@B38]; [@B64]). It is unsurprising that few regulatory mechanisms have been identified for CPS production as CPS levels are commonly regulated post-translationally through the phosphorylation of CPS export machinery ([@B61]; [@B5]). In *A. baumannii*, only two regulators of capsule production have thus far been identified; BfmRS and OmpR-EnvZ, both two component signal transduction systems which play multiple regulatory roles involved in envelope biogenesis ([@B11]; [@B52]; [@B12]). When subjected to antibiotic pressure, *A. baumannii* ATCC 17978 *cps* expression was increased in a BfmRS-dependent manner ([@B11]). Phase variation, and thus potentially CPS production, is highly regulated by the OmpR-EnvZ system in *A. baumannii* AB5075, as mutations in either OmpR or EnvZ resulted in a significant increase in opaque to translucent switching frequency ([@B52]). Although transition from translucent to opaque results in a two-fold increase in capsule thickness, transcriptomic analyses have not identified any differences in expression levels of KL genes between the two phases.

CPS as a Target for the Development of Vaccines and Treatments Against *A. baumannii*
=====================================================================================

Antibiotic (specifically cabapenem) resistant *A. baumannii* are classified a World Health Organization Priority 1 Critical organism for the development of new antimicrobials ([@B62]). Although there are no non-antibiotic treatments or vaccines licensed for *A. baumannii* at present, there is an increased interest in their development and preliminary studies look promising. Surface exposure and prevalence in pathogenic strains of *A. baumannii* makes CPS an ideal target for both antimicrobial treatments and vaccines ([@B43]). These include the development of antibody-based therapies such as prophylactic vaccines, passive immunization, and phage therapy ([@B9]).

Several studies have shown the efficacy of passive immunization in mice using a CPS-specific antibody, which is protective against bacterial challenge with 13--55% of clinical *A. baumannii* isolates ([@B43]; [@B68]; [@B31]). Additionally, inoculation with conjugate vaccines incorporating CPS glycans attached to a protein carrier elicit better immune protection than purified CPS against a diverse range of *A. baumannii* strains ([@B68]).

Interest in phage therapy to treat bacterial infections has increased in recent years in response to the current crisis of rising antimicrobial resistance. Phage therapy is attractive as a potential treatment avenue for multidrug resistant *A. baumannii* infections. For example, a phage encoding a CPS depolymerase was found to degrade the CPS of approximately 10%, four out of 38, clinical multidrug resistant *A. baumannii* tested ([@B15]). Although the host range of this phage is limited, it could be incorporated as part of a phage cocktail to maximize effectiveness or target specific outbreaks ([@B15]). A phage which selectively cleaves the linkage of *A. baumannii* CPS at a pseudaminic acid branch may be valuable for phage therapy, or to efficiently manufacture purified CPS for vaccine and antibody development ([@B31]). Phage targeting *A. baumannii* were recently shown to be stable when impregnated in burn wound care products under a range of conditions including in the presence of antimicrobials ([@B36]). However, as the majority of studies investigating *A. baumannii* CPS are usually confined to a particular *A. baumannii* strain, it is not known if these findings translate to all *A. baumannii* isolates or if they are strain or capsule type specific. Understanding what roles capsule plays in multiple strains is paramount in identifying CPS types which represent the best targets for new vaccines, or whether the development of antimicrobials targeting capsule biosynthesis pathway is indeed even feasible.

Concluding Remarks
==================

Although capsule represents an important virulence trait of *A. baumannii* there are limited data available on the role different CPS types play in causing disease. To develop effective vaccines and therapies targeting CPS, we must first gain a comprehensive understanding towards the mechanisms behind its synthesis and expression, alongside the advantages that capsule conveys to the host bacteria. This research needs to be addressed in the context of the extreme variation of CPS serotypes found in *A. baumannii*, to ensure potential interventions work against strains producing diverse CPS structures. Further studies on CPS are required to provide a platform for the development of preventative measures and treatments against this increasingly persistent and deadly human pathogen.
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